Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$5.47 +0.7%	$5.30	$2.37 ▼ $5.72	$1.23B	2.53	955,438 shs	1.11 million shs
PHVS Pharvaris	$21.09 +1.2%	$19.29	$11.51 ▼ $26.33	$1.10B	-2.81	78,249 shs	60,385 shs
SLRN Acelyrin	$2.27	$2.27	$1.85 ▼ $7.10	$229.17M	1.07	1.29 million shs	N/A
SYRE Spyre Therapeutics	$15.89 +4.2%	$16.26	$10.91 ▼ $40.26	$959.76M	2.82	616,990 shs	213,001 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	-0.18%	-0.55%	-0.55%	+60.18%	+65.55%
PHVS Pharvaris	+3.58%	-1.88%	-17.04%	+29.36%	+29.60%
SLRN Acelyrin	0.00%	0.00%	0.00%	+8.61%	-55.58%
SYRE Spyre Therapeutics	+0.59%	-5.63%	-2.80%	+3.39%	-38.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CVAC CureVac	4.3793 of 5 stars	4.1	3.0	4.9	1.9	0.0	1.3
PHVS Pharvaris	1.9048 of 5 stars	3.5	2.0	0.0	2.0	0.0	0.0
SLRN Acelyrin	2.128 of 5 stars	3.2	0.0	0.0	0.6	2.5	1.3
SYRE Spyre Therapeutics	2.4442 of 5 stars	3.6	0.0	0.0	4.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVAC CureVac	2.20	Hold	$6.83	24.92% Upside
PHVS Pharvaris	3.00	Buy	$36.20	71.65% Upside
SLRN Acelyrin	2.40	Hold	$9.60	322.91% Upside
SYRE Spyre Therapeutics	3.29	Buy	$53.40	236.06% Upside

Current Analyst Ratings Breakdown

Latest SLRN, SYRE, PHVS, and CVAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
6/26/2025	CVAC CureVac	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral	$12.00 ➝ $5.50
6/13/2025	CVAC CureVac	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$7.00 ➝ $5.00
6/12/2025	CVAC CureVac	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
6/12/2025	CVAC CureVac	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/11/2025	PHVS Pharvaris	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$32.00
6/5/2025	PHVS Pharvaris	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$27.00
5/28/2025	CVAC CureVac	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$10.00
5/14/2025	PHVS Pharvaris	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$28.00 ➝ $25.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVAC CureVac	$579.18M	2.12	$0.88 per share	6.23	$3.36 per share	1.63
PHVS Pharvaris	N/A	N/A	N/A	N/A	$5.54 per share	N/A
SLRN Acelyrin	N/A	N/A	N/A	N/A	$6.74 per share	N/A
SYRE Spyre Therapeutics	$890K	1,078.38	N/A	N/A	$7.04 per share	2.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVAC CureVac	$175.50M	$0.92	5.95	N/A	N/A	35.44%	30.89%	25.54%	8/13/2025 (Estimated)
PHVS Pharvaris	-$145.24M	-$3.01	N/A	N/A	N/A	N/A	-54.02%	-50.36%	8/13/2025 (Estimated)
SLRN Acelyrin	-$381.64M	-$2.69	N/A	N/A	N/A	N/A	-44.12%	-39.02%	8/12/2025 (Estimated)
SYRE Spyre Therapeutics	-$208.02M	-$3.40	N/A	N/A	N/A	N/A	-71.30%	-38.69%	N/A

Latest SLRN, SYRE, PHVS, and CVAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	CVAC CureVac	-$0.15	N/A	N/A	N/A	$4.27 million	N/A
8/13/2025	Q1 2025	PHVS Pharvaris	-$0.87	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	SLRN Acelyrin	-$0.71	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	SYRE Spyre Therapeutics	-$0.73	-$0.49	+$0.24	-$0.49	N/A	N/A
5/22/2025	Q1 2025	CVAC CureVac	-$0.16	-$0.24	-$0.08	-$0.24	$4.27 million	$0.94 million
5/14/2025	Q1 2025	SLRN Acelyrin	-$0.95	-$0.55	+$0.40	-$0.55	N/A	N/A
5/13/2025	Q1 2025	PHVS Pharvaris	-$0.80	-$0.89	-$0.09	-$0.89	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVAC CureVac	0.05	7.65	7.64
PHVS Pharvaris	N/A	11.10	11.10
SLRN Acelyrin	N/A	7.15	7.15
SYRE Spyre Therapeutics	N/A	6.49	6.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVAC CureVac	17.26%
PHVS Pharvaris	N/A
SLRN Acelyrin	87.31%
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
CVAC CureVac	N/A
PHVS Pharvaris	N/A
SLRN Acelyrin	13.60%
SYRE Spyre Therapeutics	6.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVAC CureVac	880	224.34 million	N/A	Optionable
PHVS Pharvaris	30	52.29 million	N/A	Not Optionable
SLRN Acelyrin	135	100.95 million	86.68 million	Optionable
SYRE Spyre Therapeutics	73	60.40 million	56.66 million	Optionable

SLRN, SYRE, PHVS, and CVAC Headlines

Recent News About These Companies

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Buy" from Brokerages

August 12 at 3:22 AM | marketbeat.com

XTX Topco Ltd Makes New Investment in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

August 9 at 3:36 AM | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Receives "Outperform" Rating from Wedbush

August 7, 2025 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Releases Quarterly Earnings Results, Beats Estimates By $0.19 EPS

August 6, 2025 | marketbeat.com

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 5, 2025 | globenewswire.com

TD Asset Management Inc Has $361,000 Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

August 5, 2025 | marketbeat.com

Jefferies Financial Group Inc. Acquires 31,900 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

August 2, 2025 | marketbeat.com

Spyre Therapeutics Announces Grants of Inducement Awards

August 1, 2025 | globenewswire.com

Spyre Therapeutics (SYRE) Projected to Post Quarterly Earnings on Wednesday

July 31, 2025 | marketbeat.com

Victory Capital Management Inc. Sells 16,230 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)

July 28, 2025 | marketbeat.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of "Buy" by Analysts

July 17, 2025 | marketbeat.com

Here's Why We're Not Too Worried About Spyre Therapeutics' (NASDAQ:SYRE) Cash Burn Situation

July 16, 2025 | finance.yahoo.com

Spyre Therapeutics (NASDAQ:SYRE) Shares Down 7.8% - Time to Sell?

July 15, 2025 | marketbeat.com

SYRE - Spyre Therapeutics Inc Trailing Returns - Morningstar

July 4, 2025 | morningstar.comM

Spyre Therapeutics Announces Grants of Inducement Awards

July 3, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE) and UnitedHealth (UNH)

June 20, 2025 | theglobeandmail.com

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward

June 18, 2025 | seekingalpha.com

Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development ...

June 17, 2025 | finanznachrichten.de

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

June 17, 2025 | prnewswire.com

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

June 16, 2025 | prnewswire.com

Spyre Therapeutics Announces Grants of Inducement Awards

June 6, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLRN, SYRE, PHVS, and CVAC Company Descriptions

CureVac NASDAQ:CVAC

$5.47 +0.04 (+0.74%)

Closing price 04:00 PM Eastern

Extended Trading

$5.49 +0.02 (+0.44%)

As of 05:00 PM Eastern

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Pharvaris NASDAQ:PHVS

$21.09 +0.25 (+1.20%)

Closing price 04:00 PM Eastern

Extended Trading

$20.63 -0.46 (-2.18%)

As of 04:29 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Acelyrin NASDAQ:SLRN

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Spyre Therapeutics NASDAQ:SYRE

$15.89 +0.64 (+4.20%)

Closing price 04:00 PM Eastern

Extended Trading

$15.88 -0.01 (-0.03%)

As of 04:10 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time